Trials / Unknown

UnknownNCT04636515

A Phase Ⅱ Study of F520 in Patients With Urothelial Carcinoma

A Phase 2, Open-label, Single-arm，Multicenter Study of F520 in Patients With Urothelial Carcinoma

Status: Unknown
Phase: Phase 2
Study type: Interventional
Enrollment: 80 (estimated)

Sponsor: Shandong New Time Pharmaceutical Co., LTD · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

This is a multicenter, Phase 2 study to evaluate the efficacy and safety of the anti- programmed cell death-1(PD-1) monoclonal antibody F520 in participants with locally advanced or metastatic Urothelial Cancer (UC).

Conditions

Locally Advanced or Metastatic Urothelial Cell Carcinoma

Interventions

Type	Name	Description
DRUG	F520	200mg，Q3W

Timeline

Start date: 2021-01-01
Primary completion: 2022-03-01
Completion: 2022-09-01
First posted: 2020-11-19
Last updated: 2020-11-19

Source: ClinicalTrials.gov record NCT04636515. Inclusion in this directory is not an endorsement.